Sabine D. Brookman-May, Professor of Urology at München University, Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences, shared a post on X:
“Roger Li about personalized therapy post BCG Moffitt Institutional series shows meaningful long-term bladder preservation is achievable, with solid PFS despite declining RFS over time.
Across available salvage options for BCG-unresponsive CIS, no clear MFS advantage of early RC over bladder-sparing approaches at the population level BCG-exposed ≠ BCG-unresponsive — repeat BCG remains SOC after exposure.
Validated biomarkers are needed to guide risk stratification and personalize post-BCG therapy.”
More from Sabine D. Brookman-May.
